Introduction
Polycythemia vera (PV) is a myeloproliferative disorder characterized by clonal proliferation of hematopoietic stem cells leading to an accumulation of erythrocytes, leukocytes and platelets within the circulation [1] . Thromboembolic and hemorrhagic complications are major causes of morbidity in PV [2] . We report a case of On routine laboratory testing, an elevated hematocrit (61.5%), leukocytosis (22.5 G/l) and thrombocytosis (990 G/l) were noted. Vasculitis (C3, C4, antinuclear antibodies, anti-DNA antibodies) and hypercoagulability (antithrombin, cardiolipin antibodies, lupus anticoagulant, protein C, protein S, factor V Leiden screening) markers were within normal limits. A hematologic evaluation, including bone marrow biopsy and cytology, confi rmed PV. Phlebotomy was performed repeatedly until hematocrit decreased to 45%.
On the 4th day after admission the patient developed acroparesthesia involving both hands, as well as erythema, swelling and tenderness of her fi ngers ( fi g. 1 d). Erythromelalgia, a frequent thrombotic complication in PV, was suspected. One day later, anisocoria and a new extensor plantar response on the left side were noted and spontaneously resolved. This episode was followed by transient paresthesia of the left arm and periorally. A repeated CT scan of the head and transcranial ultrasound examinations were within normal limits. Since hematocrit was already below 45% and platelet count was 1 800 G/l, treatment with low-dose (100 mg) aspirin and anagrelide (12 days after the hemorrhage) was started. Under this regimen no further ischemic episodes occurred. The swelling of the fi ngers resolved within a few days.
Discussion
We describe a patient with PV initially presenting with subarachnoid hemorrhage and diplopia. The history and clinical examination were compatible with a ruptured ophthalmoplegic aneurysm. However, the location of the hemorrhage was not typical for an aneurysmatic origin. Therefore a dural fi stula and an arteriovenous malformation also had to be ruled out. Cerebral angiography was within normal limits, except for caliber irregularities in several peripheral arteries. A vasculitic cause seemed unlikely because systemic vasculitis markers were normal and pathologic vessels were confi ned to the area around the hemorrhage, therefore most likely representing local vasospasms. Evaluation revealed a subacute pontomesencephalic infarct as the cause of abducens and facial nerve palsies. Initial laboratory tests were suggestive of PV, which was confi rmed in a further hematologic evaluation.
Ischemic and hemorrhagic events that occurred simultaneously in our patient are the most common complications of PV, and occur in 30-50% of PV patients [3] . Thirty to forty percent of ischemic events in PV involve the brain arteries [4] . Hemorrhages are located predominantly on mucocutaneous sites but cerebral hemorrhages including subarachnoid hemorrhage have also been described [4] . The pathogenesis of thrombotic and hemorrhagic complications in PV is poorly understood. High blood viscosity due to elevated red cell mass and/or elevated plasma viscosity, qualitative platelet abnormalities, endothelial factors as well as post-capillary venous stasis might be responsible [3] . In our patient, a causal relationship between PV and the new neurological symptoms seems plausible since diagnostic evaluation revealed no other condition leading to simultaneous hemorrhage and ischemia.
Despite repeated phlebotomies and well-controlled hematocrit ( ! 45%), the patient developed possible erythromelalgia and new transient neurologic defi cits on two occasions, most likely representing transient ischemic attacks involving the brainstem. Therefore, low-dose aspirin and platelet-reductive therapy with anagrelide were started. Low-dose aspirin has been shown to prevent thrombotic complications in patients with PV without increasing major bleeding complications [5] . In erythromelalgia low-dose aspirin is the drug of choice [6] . In our patient, under aspirin/anagrelide treatment no further ischemic episodes or hemorrhages occurred in 3 months of follow-up.
